Strategic partnerships Leverage Genomic Testing Cooperative’s cooperative model that already integrates with laboratories, hospitals, and oncology practices to identify collaboration targets among mid to large oncology networks and academic centers for expanding access to their NGS cancer testing.

Network expansion Capitalize on their recent Houston laboratory expansion to position sales efforts around national coverage, rapid turnarounds, and scalable testing across solid tumors, hematologic neoplasms, and liquid biopsy applications.

Next generation Highlight opportunities to align with Plus Therapeutics and other biopharma or device partners seeking CNSide CSF assay integration and broader NGS capabilities to improve diagnostic workflows and companion diagnostic potential.

Data collaboration Explore data integration and outcomes collaboration with partners like Cota to offer medical centers access to combined genomic and real-world evidence data, strengthening value propositions for payers and providers.

Cost and speed Position GTC’s cooperative model as a path to lower costs, faster turnaround times, and high-quality results to attract hospital systems and oncology practices looking to consolidate testing across multiple sites.